Industry Revenues:

• Biopharmaceutical Research and Development: approx. 70%
• Manufacturing and Distribution of Medications: approx. 30%

TOP 3 Markets:

• China: approx. 60%
• USA: approx. 25%
• Europe: approx. 10%

Akeso, Inc. is a leading biopharmaceutical company specializing in the research and development of innovative medications. The majority of revenues come from biopharmaceutical research and development, highlighting a strong focus on innovative therapies and clinical studies.

The Chinese market is the largest revenue generator, attributed to local presence and access to a large patient population. The USA follows as the second largest market, supported by strategic partnerships and medication approvals. Europe completes the top 3 markets, where there is also a growing demand for innovative therapies.

Production sites of Akeso, Inc.:

Akeso, Inc. mainly produces its products in China. The company has several production facilities in the country that specialize in the manufacturing of biopharmaceutical products.

These production sites are strategically positioned in China to ensure proximity to key markets and suppliers. Akeso continuously invests in expanding and modernizing its production capacities to meet the increasing demand for its products.

Focus on R&D Investments: 30% of Revenue (2024)
Expansion of Product Pipeline: 15 New Clinical Studies Planned for 2025
International Expansion: New Partnerships in Europe and North America (2024)

Akeso, Inc. is pursuing a growth strategy that heavily focuses on research and development (R&D). The company invests approximately 30% of its revenue in R&D to expand its product pipeline and develop innovative therapies.

For 2025, Akeso plans to initiate 15 new clinical studies, which aim to significantly expand the pipeline and strengthen its market position. These studies will focus on various therapeutic areas, including oncology and immunology.

In addition, Akeso is focusing on international expansion. Through new partnerships in Europe and North America, the company aims to strengthen its global presence and tap into new markets. This strategy is intended not only to promote revenue growth but also to increase brand awareness worldwide.

Main raw materials: Biopharmaceutical active ingredients, chemicals for drug manufacturing

Countries of origin: USA, Germany, China

Akeso, Inc. is a biopharmaceutical company specializing in the development and production of antibody therapies. For the production of these therapies, the company imports biopharmaceutical active ingredients and special chemicals. These materials are mainly sourced from the USA and Germany, as these countries are leading in the production of high-quality pharmaceutical raw materials. In addition, Akeso also sources materials from China, where there may be more cost-effective alternatives and where the company itself is based, providing logistical advantages.

Market Share in Immunooncology: Estimated 10% (2025)
R&D Investments: Over 30% of revenue (2024)
Drug Pipeline: 20+ in various stages of development (2025)

Akeso, Inc. has established itself as a significant player in the field of immunooncology, as evidenced by an estimated market share of approximately 10%. The company consistently invests heavily in research and development, with over 30% of revenue flowing into this area. This underscores Akeso's commitment to developing innovative solutions and strengthening its competitive position.

The extensive pipeline of over 20 drugs in various stages of development demonstrates the potential for future growth and innovation. This provides the company with a significant competitive advantage, as it is able to bring new and improved therapies to market faster than many of its competitors.

In addition, Akeso benefits from strategic partnerships and alliances that facilitate access to new technologies and markets. This further enhances the competitive advantage by expanding the company's market reach and offerings.

Institutional Investor Share: Estimated 45% (2025)
Insider Buys/Sells: No significant changes in the last quarter (2025)

The institutional investor share in Akeso, Inc. is estimated to be around 45%. This demonstrates a strong confidence from institutional investors in the company and its future prospects.

Regarding insider transactions, there were no significant buys or sells in the last quarter, indicating a stable assessment of the current company valuation by management and other insiders. This stability can be seen as a positive signal for market participants.

Market share of Akeso, Inc.: Estimate: 3-5% (2025)

Top competitors and their market shares:

1. Roche Holding AG: 15%
2. Novartis AG: 12%
3. Bristol-Myers Squibb: 10%
4. Merck & Co., Inc.: 9%
5. Pfizer Inc.: 8%
6. Johnson & Johnson: 7%
7. AstraZeneca: 6%
8. Sanofi: 5%
9. GlaxoSmithKline: 4%
10. Akeso, Inc.: 3-5%

Akeso, Inc. is an emerging biotechnology company specializing in the development of antibody therapies. Akeso's market share is relatively small compared to major pharmaceutical companies. This is because Akeso is still a relatively young company that must compete in a highly competitive market.

Akeso's moat mainly lies in its specialization in innovative antibody therapies and a strong pipeline of drugs in development. This specialization can be seen as a significant advantage as the company is able to serve niche markets and differentiate itself through innovations.

However, compared to major competitors with established brands, extensive resources, and global distribution networks, Akeso's moat is less pronounced. Major pharmaceutical companies often benefit from a broader portfolio and stronger market presence, allowing them to leverage economies of scale and exert greater market power.

Overall, Akeso has the potential to expand its market share through targeted innovations and partnerships but must continue to invest in research and development to compete with industry giants.

Revenue Growth: 22% (2024) Research and Development Expenses: 35% of Revenue (2024) Pipeline: 10 Products in Clinical Trials (2025)

Akeso, Inc. achieved an impressive revenue growth of 22% in 2024, indicating strong demand for their biopharmaceutical products. The company continues to heavily invest in research and development, with 35% of revenue allocated to this area. This demonstrates Akeso's commitment to developing innovative therapies and expanding their product pipeline.

With 10 products currently in clinical trials, Akeso has a promising pipeline that has the potential to significantly increase future revenues. This strategic focus on research and development could lead to a competitive advantage in the long term.

In summary, Akeso, Inc. presents an attractive investment opportunity due to its strong revenue growth, substantial investments in research and development, and promising product pipeline. However, potential investors should consider the risks of the biopharmaceutical industry, including regulatory hurdles and uncertainties associated with clinical trials.

Dividend: No payout (as of 2025)

Akeso, Inc. is a biopharmaceutical company that focuses on the research and development of innovative therapies. Until 2025, the company has not distributed any dividends to its shareholders. This is typical for companies in the biotechnology industry, which often reinvest their profits in research and development to expand their product pipeline and bring new drugs to the market.

The reliability of dividend payouts is therefore not guaranteed, as the company has not followed a dividend policy so far. Investors in Akeso, Inc. should rather focus on the company's growth potential and innovation strength than on regular dividend payouts.